Novo Nordisk and United Biotechnology’s China-developed triple incretin UBT-251 beat semaglutide in a Phase 2 trial, escalating competition in the global GLP-1 obesity and diabetes market. The companies reported an HbA1c reduction of up to 2.16% after 24 weeks in Chinese patients with type 2 diabetes, with UBT-251 targeting GLP-1, GIP, and glucagon receptors.